Search

Metiamide

It was an intermediate product on the path to developing cimetidine.

Cannabidivarin

CBDV has also been shown to inhibit the activity of diacylglycerol (DAG) lipase-α, the primary enzyme responsible for the synthesis of the endocannabinoid, 2-arachidonoylglycerol (2-AG) [A33296, A33347 … While the primary components of cannabis, CBD and THC, have been shown to modulate many of their physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors

Topiroxostat

Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657]. … Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended.

Zolbetuximab

[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

2,5-Dimethoxy-4-ethylamphetamine

Sarracenia Purpurea

However, the use of Sarracenia Purpurea extracts in the clinical setting are limited. … _Sarracenia purpurea_ attract and trap insects within their pitchers, or fused leaves, to consume nitrogen during the digestion process [A32509].

Etynodiol

Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed. … While etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol.

Cloxazolam

The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety.

Etesevimab

[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for … progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.

Tebipenem pivoxil

[L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy. … [L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary